|
|
Blood, 15 May 2007, Vol. 109, No. 10, pp. 4582-4585.
Prepublished online as a Blood First Edition Paper on February 1, 2007; DOI 10.1182/blood-2006-10-052308.
 Previous Article | Table of Contents | Next Article 
TRANSPLANTATION
Brief Report
Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens
Richard E. Champlin1,
Waleska S. Perez2,
Jakob R. Passweg3,
John P. Klein2,
Bruce M. Camitta4,
Eliane Gluckman5,
Christopher N. Bredeson4,
Mary Eapen2, and
Mary M. Horowitz2
1 M. D. Anderson Cancer Center, Houston, TX;
2 Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee;
3 Hôpitaux Universitaires, Geneva, Switzerland;
4 Medical College of Wisconsin, Milwaukee;
5 Hospital St Louis, Paris, France
The addition of antithymocyte globulin (ATG) to a regimen of high-dose cyclophosphamide has been advocated to enhance engraftment after allogeneic bone marrow transplantation (BMT) for severe aplastic anemia (SAA). In a prospective clinical trial, 134 patients were randomly assigned to receive cyclophosphamide alone or in combination with ATG. All patients received T-cell–replete bone marrow from an HLA-matched sibling. With a median follow-up of 6 years, the 5-year probabilities of survival were 74% for the cyclophosphamide alone group and 80% for the cyclophosphamide plus ATG group (P = .44). Graft failure and graft-versus-host disease (GVHD) rates were similar in both groups. With the survival rates achieved, this study is not adequately powered to detect significant differences between the 2 treatment groups. In conclusion, the results of allogeneic BMT for SAA have improved over time related to advances in supportive care. The addition of ATG to the preparative regimen did not significantly improve the outcome.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Desmarets, C. M. Cadwell, K. R. Peterson, R. Neades, and J. C. Zimring
Minor histocompatibility antigens on transfused leukoreduced units of red blood cells induce bone marrow transplant rejection in a mouse model
Blood,
September 10, 2009;
114(11):
2315 - 2322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Maury, A. Bacigalupo, P. Anderlini, M. Aljurf, J. Marsh, G. Socie, R. Oneto, J. R. Passweg, and on behalf of the Severe Aplastic Anemia Working Pa
Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen
Haematologica,
September 1, 2009;
94(9):
1312 - 1315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Lee, S. Joffe, A. S. Artz, R. E. Champlin, S. M. Davies, M. Jagasia, N. A. Kernan, F. R. Loberiza Jr, R. J. Soiffer, and M. Eapen
Individual Physician Practice Variation in Hematopoietic Cell Transplantation
J. Clin. Oncol.,
May 1, 2008;
26(13):
2162 - 2170.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Stelljes, S. Hermann, J. Albring, G. Kohler, M. Loffler, C. Franzius, C. Poremba, V. Schlosser, S. Volkmann, C. Opitz, et al.
Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography
Blood,
March 1, 2008;
111(5):
2909 - 2918.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bacigalupo
Aplastic Anemia: Pathogenesis and Treatment
Hematology,
January 1, 2007;
2007(1):
23 - 28.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
